Lobular carcinoma in situ.
The diagnosis of lobular carcinoma in situ (LCIS) provokes considerable anxiety in patients owing to misconceptions about this diagnosis. Initially LCIS was considered a premalignant lesion, but it is now a marker of increased risk. The number of women diagnosed with LCIS has increased in recent years most likely owing to more rigorous breast cancer screening. Implications of this diagnosis and management options are discussed in this review.
Afonso
Nelia
N
Departments of Medicine, Wayne State University School of Medicine, Alexander J. Walt Comprehensive Breast Center, Karmanos Cancer Institute, Detroit, Michigan, USA. nafonso@med.wayne.edu
Bouwman
David
D
D000328:Adult; D000367:Age Factors; D000368:Aged; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D002278:Carcinoma in Situ / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000473:pathology*; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis